BRIDGEWATER, N.J., July 27, 2020 /PRNewswire/ -- Insmed
Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases, today announced that it will release its second
quarter 2020 financial results on Thursday, August 6,
2020.
Insmed management will host a conference call for investors
beginning at 8:30 a.m. ET
on Thursday, August 6, 2020 to discuss the financial
results and provide a business update.
Shareholders and other interested parties may participate in the
conference call by dialing (888) 317-6003 (domestic) or (412)
317-6061 (international) and referencing conference ID number
9359069. The call will also be webcast live on the company's
website at www.insmed.com.
A replay of the conference call will be accessible approximately
one hour after its completion through August 20, 2020 by
dialing (877) 344-7529 (domestic) or (412) 317-0088 (international)
and referencing replay access code 10146257. A webcast of the call
will also be archived for 90 days under the Investor Relations
section of the company's website at www.insmed.com.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product,
ARIKAYCE® (amikacin liposome inhalation
suspension), is the first and only therapy approved in the
United States for the treatment of
refractory Mycobacterium avium complex (MAC) lung
disease as part of a combination antibacterial drug regimen for
adult patients with limited or no alternative treatment options.
MAC lung disease is a chronic, debilitating condition that can
cause severe and permanent lung damage. Insmed's earlier-stage
clinical pipeline includes brensocatib, a novel oral reversible
inhibitor of dipeptidyl peptidase 1 with therapeutic potential in
non-cystic fibrosis bronchiectasis and other inflammatory diseases,
and treprostinil palmitil, an inhaled formulation of a treprostinil
prodrug that may offer a differentiated product profile for rare
pulmonary disorders, including pulmonary arterial hypertension. For
more information, visit www.insmed.com.
Contact:
Investors:
Argot Partners
Laura Perry or Heather Savelle
(212) 600-1902
Insmed@argotpartners.com
Media:
Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/insmed-to-host-second-quarter-2020-financial-results-conference-call-on-thursday-august-6-2020-301096605.html
SOURCE Insmed Incorporated